Loading
A liposomal formulation locking cytarabine and daunorubicin in a fixed ratio lengthened survival compared with standard 7+3 chemotherapy in patients aged 60 to 75 with secondary or therapy-related acute myeloid leukaemia, and more of them reached transplant.
Phase 3 trial of 309 patients aged 60 to 75 with newly diagnosed high-risk or secondary AML randomised to CPX-351 or conventional cytarabine plus daunorubicin (7+3).
Median overall survival was 9.56 months with CPX-351 against 5.95 months with 7+3 (hazard ratio 0.69); remission rates were higher and outcomes after transplant were better, with a longer recovery of blood counts as the main cost.
CPX-351 is the preferred intensive induction for fit older patients with secondary or therapy-related AML in many centres, mainly as a bridge to allogeneic transplant.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Secondary and therapy-related acute myeloid leukaemia, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/